EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC 4.0

The EASEMENT study: A multicentre, observational, cross‐sectional study to evaluate patient preferences, treatment satisfaction, quality of life, and healthcare resource use in patients with multiple myeloma receiving injectable‐containing or fully oral therapies

Robert Ayto iD, Ombretta Annibali iD, Patricia Biedermann iD, Montserrat Roset iD, Emilio Sánchez iD, Rami Kotb

European Journal of Haematology · 2024

DOI: 10.1111/ejh.14180 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Haematology, 2024. Verfasst von Robert Ayto und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Queen Alexandra Hospital, Portsmouth, UK. Hauptthemen laut MEDLINE: Multiple Myeloma, Quality of Life, Patient Preference, Patient Satisfaction. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals, U.S.A., Inc., Lexington, MA, Takeda Pharmaceuticals International.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

As multiple myeloma (MM) therapies advance, understanding patients', caregivers', and physicians' perspectives on, and satisfaction with, available treatment options and their impact on quality of life (QoL), is important.

Methods

EASEMENT is a real‐world, observational, cross‐sectional study conducted in 19 sites within the UK, Canada, and Italy using retrospective chart reviews and surveys. Enrolled patients had clinical history available since diagnosis and had received ≥1 cycle of their current line of therapy. Primary objectives were to describe patient/caregiver QoL (EQ‐5D‐5L questionnaire), patient preference for oral/injectable therapies (single discrete‐choice question), and patient satisfaction (TSQM‐9 questionnaire).

Results

Between October 2018 and March 2020, 399 patients were enrolled ( n = 192 newly diagnosed multiple myeloma [NDMM], n = 206 relapsed/refractory multiple myeloma [RRMM], n = 1 missing). Among NDMM and RRMM patients, 78%/22% and 42%/58% were receiving injectables/orals, respectively. Both NDMM and RRMM patients significantly preferred orals versus injectables ( p < .0001). No significant differences were reported in treatment satisfaction or QoL, but treatment convenience favoured orals over injectables with near significance ( p = .053).

Conclusion

MM patients perceived greater convenience and preference for orals versus injectables. Oral treatments are useful for patients who cannot or prefer not to travel to clinics, or cannot perform self‐injection within the community.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaQuality of LifePatient PreferencePatient SatisfactionHumansCross-Sectional StudiesMaleFemaleAgedAdministration, OralMiddle AgedSurveys and QuestionnairesInjectionsAged, 80 and overHealth ResourcesRetrospective Studies

Stichwörter der Autor:innen

ixazomibmultiple myelomaobservational study

Autor:innen und Institutionen

  • Department of Haematology, Queen Alexandra Hospital, Portsmouth, UK.
  • Hematology, Stem Cell Transplantation, Fondazione Policlinico Universitario Campus Bio Medico di Roma, Rome, Italy.
  • Medical Affairs, Europe & Canada, Takeda Pharmaceuticals International AG, Zurich, Switzerland.
  • Real World Solutions, IQVIA, Barcelona, Spain.
  • Medical Oncology & Hematology, CancerCare Manitoba, Winnipeg, Manitoba, Canada.

ORCID-Profile: Robert Ayto, Ombretta Annibali, Patricia Biedermann, Montserrat Roset, Emilio Sánchez

Förderung

  • Takeda Pharmaceuticals International AG
  • Takeda Pharmaceuticals, U.S.A., Inc., Lexington, MA
  • Takeda Pharmaceuticals International

Zitieren

APA

Ayto, R., Annibali, O., Biedermann, P., Roset, M., Sánchez, E., & Kotb, R. (2024). The EASEMENT study: A multicentre, observational, cross‐sectional study to evaluate patient preferences, treatment satisfaction, quality of life, and healthcare resource use in patients with multiple myeloma receiving injectable‐containing or fully oral therapies. European Journal of Haematology. https://doi.org/10.1111/ejh.14180

Vancouver

Ayto R, Annibali O, Biedermann P, Roset M, Sánchez E, Kotb R. The EASEMENT study: A multicentre, observational, cross‐sectional study to evaluate patient preferences, treatment satisfaction, quality of life, and healthcare resource use in patients with multiple myeloma receiving injectable‐containing or fully oral therapies. European Journal of Haematology. 2024. doi:10.1111/ejh.14180

BibTeX
@article{Ayto2024,
  author = {Ayto, Robert and Annibali, Ombretta and Biedermann, Patricia and Roset, Montserrat and Sánchez, Emilio and Kotb, Rami},
  title = {The EASEMENT study: A multicentre, observational, cross‐sectional study to evaluate patient preferences, treatment satisfaction, quality of life, and healthcare resource use in patients with multiple myeloma receiving injectable‐containing or fully oral therapies},
  journal = {European Journal of Haematology},
  year = {2024},
  doi = {10.1111/ejh.14180}
}
Kostenlos starten →